Sunitinib is an oral small-molecule tyrosine kinase inhibitor (TKI) that targets and blocks the signaling pathways of multiple selected receptor tyrosine kinases (RTKs). Sunitinib was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GITS) on January 26, 2006.

    During the investigation on the synthesis of pharmaceutically pure sunitinib L-malate based on the procedure described in EP 1255752B1 (Sugen Inc. and Pharmacia & Upjohn Co.) the physicochemical studies of sunitinib as well as its potential degradation products and process-related impurities were performed. The structure elucidation of the compounds was accomplished by means of the following techniques: NMR, IR and MS. Furthermore, X-ray single-cristal studies of sunitinib unambiguously proved the structure. A selective HPLC method for the determination of chemical purity of sunitinib was applied.

Research Project is supported by European Union, Project no UDA-POIG.01.03.01-14-069/08-00, 26.02.2009„Innovative technologies of oncological medicines of special therapeutic and social importance”.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/25496 must be provided.

1. The comparison of the stability indicating  two HPLC methods and their application for the determination of bosentan in coated tablets 
2. Influence of the side chain on the cytotoxicity of betulin derivatives
3. Synthesis of new 5H-indolo[2,3-b]quinoline derivatives with a high selective cytotoxic activity
4. Hplc study of Cilostazol tablets: assay and release profile determination
5. What modern crystallography can add to pharmaceutical research?
6. Improved manufacturing process of bosentan monohydrate.
7. Characterization of dutasteride polymorphic forms
8. Validation of HPLC methods for analyzing the chemical purity of cilostazol
9. Identification of degradation products of cilostazol drug substance
10. N-terminal amidinated derivatives of the cyclic 1,4-ureido-deltorphin analogues: the synthesis and  receptor binding studies
11. Preparation and physicochemical properties of crystalline forms and amorphous pemetrexed disodium
12. Assessment of selected synthesis of bosentan towards elimination of known impurities.
13. New cyclic dermorphin analogues containing a carbonyl bridge
14. Investigation of unknown impurities in cyclic dermorphin analogue by HPLC-MS
15. 5H-indolo-[2,3-b]quinolines loaded polymeric micelles
16. Development and validation of HPLC method. Review of selected cases.
17. Efficient preparation of a key intermediate in the exemestane synthesis
18. Distinguishing between polymorphic forms of linezolid by solid-phase electronic and vibrational circular dichroism
19. Preparation of protoaescigenin from escin.
20. Synthesis and biological evaluation of new amino acid and dipeptide derivatives of neocryptolepine as anticancer agents. 
21. Experimental and theoretical charge density studies on a model analogue of vitamin D
22. Determination of reaction progress in synthesis of EE-3 by NMR technique
23. The synthesis of ezetimibe with high stereochemical purity
24. Validation of a HPLC method for LI-S analysis
25. HPLC Methods for Stress Testing of ZL-S Drug Substances
26. Structural characterization of PX-S
27. A novel synthesis of 19-nor analogs of vitamin D
28. New amino acid and peptide derivatives of 5H-indolo[2,3-b]quinoline and their biological activity.
29. Quantification of active substance in drug by Rietveld analysis
30. The Crystal Structure of distrontium salt of 5-[bis(carboxymethyl)amino]-3-carboxymethyl-4-cyano-2-thiophenecarboxylic acid
31. A novel synthesis of antineoplastic drugs docetaxel and paclitaxel
32. High-yielded method of synthesis of voriconazole.
33. Optimization of AR-3 synthesis
34. New amino acid derivatives of 6H-indolo[2,3-b]quinolines
35. Redox processes of dithiolated tetraazamacrocyclic complexes of Ni(II) and Cu(II) in solution and immobilized on gold electrodes
36. Charge Density Studies of Tetraazamacrocyclic Complexes of Copper(II) and Nickel(II)
37. Sigma Cutoff - and What Lies Behind
38. CHARACTERIZATION OF ARIPIPRAZOLE SOLVATE WITH ETHANOL AND POLYMORPHIC FORMS PRODUCED DURING ITS HEATING
39. THE VALIDATION OF ANALYTICAL METHODS OF A PHARMACEUTICAL ACTIVE SUBSTANCE PRODUCED IN SMALL SCALE PLANT (SSP). THE EXAMPLE OF PIOGLITAZONE HYDROCHLORIDE.
40. THE STUDY OF ROTAMERS IN PRILS AND PRILATES BY HPLC AND NMR METHODS
41. Fine-tuning of properties of bismacrocyclic dinuclear cyclidene receptors by N-methylation.